Atara Biotherapeutics (ATRA) Current Assets (2013 - 2026)

Atara Biotherapeutics' Current Assets history runs 14 years deep, the most recent figure standing at $12.2 million for Q1 2026.

• Quarterly Current Assets fell 55.22% year-over-year to $12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (down 55.22% YoY) and the FY2025 annual result came in at $12.2 million, down 81.18% from the prior year.
• Current Assets was $12.2 million for Q1 2026 at Atara Biotherapeutics, roughly flat from $12.2 million in the prior quarter.
• Across five years, Current Assets topped out at $347.0 million in Q2 2022 and bottomed at $12.2 million in Q1 2026.
• A 5-year average of $133.9 million and a median of $101.9 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets fell 11.56% — and 2025, when it sank 81.18%.
• Atara Biotherapeutics' Current Assets stood at $295.1 million in 2022, then tumbled by 65.48% to $101.9 million in 2023, then plunged by 36.3% to $64.9 million in 2024, then sank by 81.18% to $12.2 million in 2025, then declined by 0.32% to $12.2 million in 2026.
• Business Quant data shows ATRA's Current Assets at $12.2 million in Q1 2026, $12.2 million in Q4 2025, and $18.4 million in Q3 2025.